Spots Global Cancer Trial Database for pharmacologic actions
Every month we try and update this database with for pharmacologic actions cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo | NCT01512173 | Infantile Heman... | propranolol gel Placebo | 35 Days - 150 Days | Pierre Fabre Dermatology | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo | NCT01512173 | Infantile Heman... | propranolol gel Placebo | 35 Days - 150 Days | Pierre Fabre Dermatology | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | NCT02010606 | Glioblastoma Glioblastoma Mu... Glioma Astrocytoma Brain Tumor | Dendritic cell ... Dendritic cell ... | 18 Years - | Cedars-Sinai Medical Center | |
| Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) | NCT01201811 | Myelodysplastic... | Azacitidine | 18 Years - | Celgene | |
| Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | NCT02010606 | Glioblastoma Glioblastoma Mu... Glioma Astrocytoma Brain Tumor | Dendritic cell ... Dendritic cell ... | 18 Years - | Cedars-Sinai Medical Center | |
| An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer | NCT01397305 | Rectal Cancer | [6R] 5,10-methy... Pemetrexed | 18 Years - | Isofol Medical AB | |
| Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) | NCT02252159 | MPN (Myeloproli... | 18 Years - | Incyte Corporation | ||
| Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) | NCT02134015 | Lung Cancer Non-small Cell ... | Patritumab Erlotinib Placebo | 20 Years - | Daiichi Sankyo | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) | NCT02112656 | Hepatocellular ... | ThermoDox Dummy infusion | 18 Years - | Imunon | |
| Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy | NCT02765594 | Primary IgA Nep... | Hydroxychloroqu... Valsartan | 18 Years - 60 Years | Peking Union Medical College Hospital | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment | NCT02301104 | Advanced Solid ... | TAS-102 | 18 Years - | Taiho Oncology, Inc. | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer | NCT02385617 | Esophageal Neop... Stomach Neoplas... Weight Loss Malnutrition | Octreotide Placebo | 18 Years - 100 Years | St. James's Hospital, Ireland | |
| A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors | NCT01764087 | Unspecified Adu... Gastric Cancer Breast Cancer | KX2-391 and Pac... | 20 Years - | Hanmi Pharmaceutical Company Limited | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| High-dose Vitamin D Supplementation for ADT-induced Side Effects | NCT02064946 | Prostatic Neopl... Bone Mineral De... | vitamin D Placebo | 60 Years - 99 Years | University of Rochester | |
| A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma | NCT00102609 | Soft Tissue Sar... Sarcoma Neoplasms, Conn... Neoplasms by Hi... Neoplasms | Doxorubicin Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer | NCT01515046 | Pancreatic Neop... Pancreatic Canc... | Gemcitabine wit... | 18 Years - | University of Iowa | |
| Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment | NCT02301104 | Advanced Solid ... | TAS-102 | 18 Years - | Taiho Oncology, Inc. | |
| Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | NCT00773747 | Multiple Myelom... | Vorinostat bortezomib placebo to vori... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer | NCT00838578 | Colorectal Canc... | KRN330 Irinotecan | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | NCT01384253 | Breast Neoplasm... Peritoneal Neop... Ovarian Neoplas... Pancreatic Neop... Stomach Neoplas... | ²¹²Pb-TCMC-Tras... trastuzumab | 19 Years - | Orano Med LLC | |
| SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | NCT00365274 | Anaplastic Larg... | Cyclophosphamid... Doxorubicin hyd... vincristine sul... prednisone SGN-30 | 18 Years - | National Cancer Institute (NCI) | |
| Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D | NCT01166763 | Breast Cancer | vitamin D3 | - 55 Years | University of Kansas Medical Center | |
| Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA | NCT01550510 | Stage IV Colore... | Ascorbic Acid Irinotecan | 18 Years - | Thomas Jefferson University | |
| A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) | NCT01799499 | Non Muscle Inva... | TC-3 hydrogel TC-3 hydrogel TC-3 hydrogel | 21 Years - | UroGen Pharma Ltd. | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | NCT01990534 | Hodgkin Lymphom... | Brentuximab Ved... | 18 Years - | Takeda | |
| High-dose Vitamin D Supplementation for ADT-induced Side Effects | NCT02064946 | Prostatic Neopl... Bone Mineral De... | vitamin D Placebo | 60 Years - 99 Years | University of Rochester | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients | NCT01611961 | Advanced Cancer | DT-LM docetaxel | 18 Years - 65 Years | Shenyang Pharmaceutical University | |
| High-dose Vitamin D Supplementation for ADT-induced Side Effects | NCT02064946 | Prostatic Neopl... Bone Mineral De... | vitamin D Placebo | 60 Years - 99 Years | University of Rochester | |
| An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis | NCT01743560 | Oestrogen Recep... | RAD001 Exemestane | 18 Years - | Novartis | |
| Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA | NCT01550510 | Stage IV Colore... | Ascorbic Acid Irinotecan | 18 Years - | Thomas Jefferson University | |
| Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors | NCT01215578 | Neuroendocrine ... Pancreatic Neop... Advanced Diseas... Sunitinib | Sutent | 18 Years - | Assistance Publique - Hôpitaux de Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
